Physician profile
Lio Yu
NPI 1932144995
$924.13
in general payments reported to CMS, 2019-2025
15 companies · $60.25 in 2025
The $60.25 reported for 2025 was less than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $161 · 2020: $387 · 2021: $117 · 2022: $120 · 2023: $47.87 · 2024: $30.97 · 2025: $60.25.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $139.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $154.07 | 2020-2024 | Dupixent |
| Galderma Laboratories, L.P. | $124.96 | 2020 | |
| Novocure INC. | $112.99 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $84.32 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $80.58 | 2020-2022 | |
| Genzyme Corporation | $74.64 | 2021-2023 | |
| Incyte Corporation | $67.73 | 2022-2025 | Opzelura |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $59.94 | 2021-2025 | Cabtreo |
| Biofrontera INC. | $33.68 | 2019-2020 | |
| Almirall LLC | $29.86 | 2019-2021 | |
| Mayne Pharma Commercial LLC | $28.18 | 2020 | |
| Epi Health, LLC | $22.21 | 2020 | |
| Janssen Biotech, INC. | $19.24 | 2023 | Simponi Aria, Remicade, Stelara |
| Journey Medical Corporation | $16.07 | 2022 | |
| Smith+Nephew, INC. | $15.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lio Yu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.